Immunogenicity of Quadrivalent HPV Vaccine Among Girls 11 to 13 Years of Age Vaccinated Using Alternative Dosing Schedules: Results 29 to 32 Months After Third Dose

Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam

(2013) Carol E Levin et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women

(2013) Simon R. M. Dobson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania

(2012) Wilm Quentin et al.   BMC Medicine

Assessment of eight HPV vaccination programs implemented in lowest income countries

(2012) Joël Ladner et al.   BMC PUBLIC HEALTH

Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10–14 Years

(2012) Tino F. Schwarz et al.   JOURNAL OF ADOLESCENT HEALTH

Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination

(2012) Kinga K. Smolen et al.   VACCINE

A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines

(2012) John T. Schiller et al.   VACCINE

Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries

(2011) D Scott LaMontagne et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Human Papillomavirus 16 (HPV 16) and HPV 18 Antibody Responses Measured by Pseudovirus Neutralization and Competitive Luminex Assays in a Two- versus Three-Dose HPV Vaccine Trial

(2011) Mel Krajden et al.   Clinical and Vaccine Immunology

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule

(2011) Barbara Romanowski et al.   Human vaccines & immunotherapeutics

Immunogenicity and Reactogenicity of Alternative Schedules of HPV Vaccine in Vietnam

(2011) Kathleen M. Neuzil   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine

(2011) Aimée R. Kreimer et al.   JNCI-Journal of the National Cancer Institute

Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women

(2010) Tiina Petäjä et al.   INTERNATIONAL JOURNAL OF CANCER

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

(2009)   LANCET

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET

Immunobiology of HPV and HPV vaccines

(2008) Margaret Stanley   GYNECOLOGIC ONCOLOGY

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

(2008) Elmar A. Joura et al.   VACCINE

Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines

(2007) Cosette M. Wheeler et al.   VACCINE